Patent · US Active

Vaccine protection assay

US7955817B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Isabel De Vleeschauwer · Rixensart, BE
Nathalie Durant · Rixensart, BE
Jan Poolman · Broek in Waterland, NL
Vincent Weynants · Wavre, BE

Key dates

Filing date	Aug 31, 2006
Grant date	Jun 7, 2011
Priority date	—
Expiry date	Nov 13, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S435/81
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.